Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Derek Dustin"'
Autor:
Ashley Aaroe, Razelle Kurzrock, Gaurav Goyal, Aaron Michael Goodman, Harsh Patel, Gordon J Ruan, Gary Ulaner, Jason R. Young, Ziyi Li, Derek Dustin, Ronald S. Go, Eli L Diamond, Filip Janku
Publikováno v:
Blood Advances.
Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs) for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histio
Autor:
Jean Paul De La O, Hangqing Lin, Shunqiang Li, Beom-Jun Kim, Alana L. Welm, David Edwards, Doug W. Chan, Sandra L. Grimm, Guowei Gu, Dan Liu, Derek Dustin, Amanda Beyer, Suzanne A. W. Fuqua, Thomas Gonzalez, Cristian Coarfa, Sarah Herzog, Matthew J. Ellis
Publikováno v:
British Journal of Cancer
Background Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated with aromatase inhibitors (AI) in the metastatic setting. Acquired ESR1 mutations ar
Autor:
Yassine Rechoum, Jin-Ah Kim, Shunqiang Li, Sarah Herzog, Filip Janku, David Edwards, Gordon B. Mills, Helen J. Huang, W. Fraser Symmans, Charles E. Foulds, Luca Gelsomino, Suzanne A. W. Fuqua, Cristian Coarfa, Sandra L. Grimm, Lili Du, Meng Gao, Xiang Zhang, Susan G. Hilsenbeck, Hin Ching Lo, Sebastiano Andò, Thomas Gonzalez, Lin Tian, Alyssa Alaniz, Amanda Beyer, Guowei Gu, Dan Liu, Derek Dustin, Anna Tsimelzon, Natalie M. Fernandez, Jun Xu, Ralf Kittler
Publikováno v:
Oncogene
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer (MBC), and confer clinical resistance to aromatase inhibitors (AIs). Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transi
Autor:
Meng Gao, Hin Ching Lo, Shunqiang Li, David Edwards, W. Fraser Symmans, Gordon B. Mills, Cristian Coarfa, Guowei Gu, Charles E. Foulds, Dan Liu, Alyssa Alaniz, Amanda Beyer, Sandra L. Grimm, Derek Dustin, Lili Du, Lin Tian, Anna Tsimelzon, Jin-Ah Kim, Helen J. Huang, Ralf Kittler, Sebastiano Andò, Susan G. Hilsenbeck, Luca Gelsomino, Suzanne A. W. Fuqua, Xiang Zhang, Jun Xu, Natalie M. Fernandez, Thomas Gonzalez, Yassine Rechoum, Sarah Herzog, Filip Janku
Publikováno v:
Oncogene. 41:460-460
Publikováno v:
Current Opinion in Pharmacology. 31:97-103
In recent years, clinical trials investigating new drugs and therapeutic combinations have led to promising advances in breast cancer therapy. Subtyping breast cancers into hormone receptor (HR) positive, epidermal growth factor receptor (HER2) posit
Publikováno v:
Cancer
The acquisition of ligand-independent ESR1 mutations during aromatase inhibitor (AI) therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7ce1b0939bfbe8aaa7115eca6fa313f
https://europepmc.org/articles/PMC6788940/
https://europepmc.org/articles/PMC6788940/
Autor:
Amanda Beyer, Guowei Gu, Matthew J. Ellis, David Edwards, Derek Dustin, Doug W. Chan, Suzanne A. W. Fuqua
Publikováno v:
Cancer Research. 80:PD7-03
Background: Approximately half of women with estrogen receptor (ER)-positive breast cancer who undergo adjuvant endocrine therapy (ET) develop disease progression and metastasis. Studies have revealed that up to 40% of metastatic patients develop tum
Publikováno v:
Horm Cancer
After nearly 20 years of research, it is now established that mutations within the estrogen receptor (ER) gene, ESR1, frequently occur in metastatic breast cancer and influence response to hormone therapy. Though early studies presented differing res
Publikováno v:
Chem. Commun.. 50:4827-4830
We report here a facile approach to prepare filamentous supramolecular peptide–drug conjugates with precise drug/carrier stoichiometry, nearly 100% loading efficiency and exceptional anti-cancer drug efficacy for chemotherapy.
Autor:
Amanda Beyer, Guowei Gu, Derek Dustin, David Edwards, Arnoldo Corona-Rodriguez, Suzanne A. W. Fuqua, Doug W. Chan, Matthew J. Ellis
Publikováno v:
Cancer Research. 79:921-921
Background: Approximately half of women with estrogen receptor (ER)-positive breast cancer who undergo adjuvant endocrine therapy (ET) develop disease progression and metastasis. Studies have revealed that up to 40% of metastatic patients develop tum